表紙
市場調查報告書

細胞治療、先進治療領域的供應鏈管理市場:2019-2030年

Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological Solutions (Cell Orchestration Platforms, Enterprise Manufacturing Systems, Inventory Management Systems, Laboratory Information Management Systems, Logistics

出版商 ROOTS ANALYSIS 商品編碼 915453
出版日期 內容資訊 英文 427 Pages
商品交期: 最快1-2個工作天內
價格
細胞治療、先進治療領域的供應鏈管理市場:2019-2030年 Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological Solutions (Cell Orchestration Platforms, Enterprise Manufacturing Systems, Inventory Management Systems, Laboratory Information Management Systems, Logistics
出版日期: 2019年10月31日內容資訊: 英文 427 Pages
簡介

本報告提供細胞治療、先進治療領域的供應鏈管理的市場調查,細胞治療、先進治療概要,該領域的主要的供應鏈管理軟體解決方案,引進推動因素與阻礙,數位技術的重要性,用途、解決方案類型、引進方式等各種區分的市場規模的變化、預測,競爭環境,主要企業的簡介,投資分析,企業間的聯盟、合作等趨勢,專家的見解等彙整資料。

第1章 序文

第2章 摘要整理

第3章 簡介

  • 背景
  • 簡介:細胞治療、先進治療
  • 細胞治療、先進治療領域的供應鏈
  • 細胞治療、先進治療領域的供應鏈管理軟體解決方案
    • COP (Cell Orchestration Platform)
    • 企業製造系統
    • 庫存管理系統
    • 實驗室資訊管理系統
    • 物流管理系統
    • 患者管理系統
    • 品管系統
    • 物流追蹤系統
  • 成長因素、障礙
  • 數位技術的出現
    • 區塊鏈技術
    • IoT
    • AR
    • 巨量資料分析
    • AI

第4章 目前市場環境

  • 概要
  • 整體市場環境
    • 各軟體解決方案類型
    • 各規格、優點
    • 各用途
    • 各終端用戶
    • 各引進模式
    • 各管理規模
    • 法規認證、認證
  • 開發者環境
    • 各成立年份
    • 各本部所在地
    • 各企業規模
    • 各支援服務
    • 主要開發者:各軟體解決方案數分析

第5章 企業競爭力分析

  • 概要
  • 前提條件、主參數
  • 解決方案供應商:競爭力分析

第6章 核心供應鏈管理軟體解決方案:企業簡介

  • 概要
  • Brooks Life Sciences
  • Cryoport
  • MasterControl
  • SAP
  • Savsu Technologies
  • TraceLink

第7章 COP (Cell Orchestration Platform):新興趨勢、主要企業的簡介

  • 概要
  • 供應鏈編配平台
    • 主要功能
    • 優點
    • 實行策略
  • 供應鏈編配平台:Twitter上的趨勢
  • 主要企業
    • Be The Match BioTherapiesR
    • Clarkston Consulting
    • Haemonetics
    • Hypertrust Patient Data Care
    • Lykan Bioscience
    • MAK-SYSTEM
    • sedApta Group
    • Stafa Cellular Therapy
    • Title 21 Health Solutions
    • TrakCel
    • Vineti

第8章 資金、投資分析

  • 概要
  • 資金類型
  • 最近的資金投入範例
  • 總論

第9章 聯盟、合作

  • 概要
  • 聯盟模式
  • 聯盟、合作分析:各種區分

第10章 平台有效利用案例

第11章 價值鏈分析

第12章 相關利益者的需求分析

第13章 成本節減分析

第14章 市場預測

  • 概要
  • 整體市場分析、預測
    • 各用途
    • 各終端用戶
    • 各軟體解決方案類型
    • 各引進模式
    • 各地區
  • 整體市場分析、預測:各用途、軟體解決方案類型、引進模式
    • 捐贈者申請資格評估
      • 患者管理系統
      • 供應鏈編配平台
    • 樣品回收
      • 庫存管理系統
      • 實驗室資訊管理系統
      • 物流管理系統
      • 品管 系統
      • 供應鏈編配平台
    • 製造
      • 企業製造系統市場
      • 庫存管理系統市場
      • 實驗室資訊管理系統市場
      • 品管 系統市場
      • 供應鏈編配平台市場
    • 物流
      • 物流管理系統市場
      • 供應鏈編配平台市場
    • 患者檢驗、治療跟蹤
      • 患者管理系統市場
      • 供應鏈編配平台

第15章 專家的見解

第16章 總論

第17章 附錄:其他供應鏈管理軟體解決方案的清單

第18章 附錄:圖表資料

第19章 附錄:企業、組織清單

目錄

Title:
Cell and Advanced Therapies Supply Chain Management Market, 2019-2030:
Focus on Technological Solutions (Cell Orchestration Platforms, Enterprise Manufacturing Systems, Inventory Management Systems, Laboratory Information Management Systems, Logistics Management Systems, Patient Management Systems, Quality Management Systems, Tracking & Tracing Systems, and Other Software).

Overview:

Advanced therapy medicinal products, such as cell and gene therapies, have revolutionized healthcare practices. The introduction of such treatment options has led to a paradigm shift in drug development, production and consumption. Moreover, such therapies have actually enabled healthcare providers to treat several difficult-to-treat clinical conditions. In the past two decades, more than 30 such therapy products have been approved; recent approvals include Zolgensma® (2019), RECELL® System (2018), AmnioFix® (2018), EpiFix® (2018), EpiBurn® (2018), Alofisel® (2018), LUXTURNA™ (2017), Yescarta® (2017), and Kymriah® (2017). Further, according to a report published by The Alliance for Regenerative Medicine in 2019, more than 1,000 clinical trials are being conducted across the globe by over 900 companies. In 2018, around USD 13 billion was invested in this domain, representing a 73% increase in capital investments in this domain, compared to the previous year. It is worth highlighting that, based on an assessment of the current pipeline of cell therapies and the historical clinical success of such products, it is likely that around 10-20 advanced therapies are approved by the US FDA each year, till 2025.

The commercial success of cell and advanced therapies is not only tied to whether they are capable of offering the desired therapeutic benefits, but also on whether the developers are able to effectively address all supply chain requirements. The advanced therapy medicinal products supply chain is relatively more complex compared to the conventional pharmaceutical supply chain. As a result, there are a number of risks, such as possible operational inefficiencies, capacity scheduling concerns, process delays leading to capital losses, and deliverable tracking-related issues, which need to be taken into consideration by therapy developers. This has generated a need for bespoke technological solutions, which can be integrated into existing processes to enable the engaged stakeholders to oversee and manage the various aspects of the cell and advanced therapies supply chain, in compliance to global regulatory standards. Over the years, several innovative, software-enabled systems, offering supply chain orchestration and needle-to-needle traceability, have been developed. The market has also recently witnessed the establishment of numerous partnerships, most of which are agreements between therapy developers and software solutions providers. Further, given the growing demand for cost-effective personalized medicinal products, and a myriad of other benefits of implementing such software solutions, the niche market is poised to grow significantly in the foreseen future.

Scope of the Report:

The ‘Cell and Advanced Therapies Supply Chain Management Market: Focus on Technological Solutions, 2019-2030' report features an extensive study of the growing supply chain management software solutions market. The focus of this study is on software systems, including cell orchestration platforms (COP), enterprise manufacturing systems (EMS), inventory management systems (IMS), laboratory information management systems (LIMS), logistics management systems (LMS), patient management systems (PMS), quality management systems (QMS), tracking and tracing software (TTS), and other such platforms that are being used to improve / optimize various supply chain-related processes of cell and advanced therapies. Amongst other elements, the report features:
  • A detailed assessment of the current market landscape, featuring a comprehensive list of over 160 technological platforms that are being used to manage the cell and advanced therapies supply chain, along with information on the different types of software systems (COP, EMS, IMS, LIMS, LMS, PMS, QMS, TTS, and others), their key specifications and benefits (chain of identity and custody, compatibility and integration, data management and analytics, regulatory compliance, reliability and security, scalability, software-as-a-service, traceability, user-friendliness, workflow management, and others), affiliated modes of deployment (cloud and on-premises), scale of management (small enterprise, mid-size enterprise and large enterprise), end users (biobanks, cell therapy labs, hospitals, research institutes, commercial organizations, and others), applications (ordering and scheduling, sample collection, manufacturing, logistics, and patient verification and treatment follow-up), regulatory certifications / accreditations (21 CFR Part 11, CLIA, FACT-JACIE, GAMP 5, GDPR, HIPAA, and others), and key support services offered (customization, installation / implementation, maintenance, training / technical support, upgradation, validation and testing, and others).
  • An insightful company competitiveness analysis, taking into consideration the supplier power (based on their employee base and years of experience in the industry) and portfolio-related parameters, such as number of software solutions offered, affiliated modes of deployment, scale of management, end users, applications, regulatory certifications / accreditations, support services offered, and key platform specifications and benefits.
  • Comprehensive profiles of industry players that are currently offering software solutions for supply chain management, featuring an overview of the company, its financial information (if available), and a detailed description of its software system(s). Each profile also includes a list of recent developments, highlighting the key achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth, in the foreseen future.
  • A detailed review of the cell and advanced therapies supply chain, offering insights on the processes associated with various stages, such as donor eligibility assessment, sample collection, manufacturing, logistics, and patient verification and treatment follow-up, along with information on cost requirements and existing opportunities for improvement in the supply chain management practices.
  • A qualitative assessment of the current and long-term needs of different stakeholders (patients, healthcare providers, collection centers, manufacturers, logistics service providers and regulators / payers) involved in the cell and advanced therapies supply chain, featuring a summary of the diverse needs and areas of concern, along with our opinion (based on past and prevalent trends) on how the industry is preparing to address such issues.
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings received by companies that are engaged in this field.
  • An analysis of the partnerships that have been established in the domain, in the period between 2014 and Q3 2019, covering software licensing agreements, mergers and acquisitions, product development agreements, product integration agreements, distribution agreements, asset purchase agreements, and other relevant deals.
  • A detailed analysis of the platform utilization use cases where aforementioned software systems were leveraged by various stakeholders in the domain, in the period between 2014 and Q3 2019, highlighting the ways in which companies have implemented such systems to improve / optimize various supply chain-related processes of cell and advanced therapies.
  • An in-depth analysis of the cost saving potential across various processes of the cell and advanced therapies supply chain that can be brought about by the implementation of bespoke and integrated technological solutions / software systems.
  • A case study on COPs, featuring insights on their key functions and implementation strategies, while also considering their strategic position and connectivity with other adjacent systems within the cell and advanced therapies supply chain. In addition, it provides a brief discussion on the growing popularity of COPs on the social media platform, Twitter.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the supply chain management software solutions market. Based on multiple parameters, such as number of cell and advanced therapies under development, expected pricing, likely adoption rates, and potential cost saving opportunities from different software systems, we have developed informed estimates of the evolution of the market, over the period 2019-2030. In addition, we have provided the likely distribution of the current and forecasted opportunity across [A] different software systems (COP, EMS, IMS, LIMS, LMS, PMS, QMS, and TTS), [B] applications (donor eligibility assessment, sample collection, manufacturing, logistics, and patient verification and treatment follow-up), [C] modes of deployment (cloud and on-premises), [D] end users (biobanks, cell therapy labs, hospitals, research institutes, and commercial organizations), and [E] key geographical regions (North America, Europe and Asia-Pacific). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry's evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Bryan Poltilove (Vice President and General Manager, Thermo Fisher Scientific)
  • Jacqueline Barry (Chief Clinical Officer, Cell and Gene Therapy Catapult)
  • Jill Maddux (Director, Cell and Gene Therapy Product Strategy, McKesson) and Divya Iyer (Senior Director, Corporate Strategy and Business Development, McKesson)
  • Martin Lamb (Chief Business Officer, TrakCel)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the cell and advanced therapies supply chain solutions market in the mid to long term.

Chapter 3 is an introductory chapter that presents a general overview of the cell and advanced therapies domain, along with details on the various types of such products and the current therapy landscape. It features a detailed discussion on the cell and advanced therapies supply chain and key challenges related to different processes / stakeholders involved in this segment of the industry. The chapter also provides information on various software-enabled systems, highlighting their key advantages and associated challenges. Further, the chapter describes the key growth drivers and roadblocks related to the use of such solutions in the cell and advanced therapies supply chain, offering insights on the emergence of advanced, digital technologies in the domain, as well.

Chapter 4 includes information on more than 160 technological platforms that are currently being used for managing the critical intricacies within the cell and advanced therapies supply chain. It features detailed information on the different types of software systems (COP, EMS, IMS, LIMS, LMS, PMS, QMS, TTS, and others), their key specifications and benefits (chain of identity and custody, compatibility and integration, data management and analytics, regulatory compliance, reliability and security, scalability, software-as-a-service, traceability, user-friendliness, workflow management, and others), affiliated modes of deployment (cloud and on-premises), scale of management (small enterprise, mid-size enterprise and large enterprise), end users (biobanks, cell therapy labs, hospitals, research institutes, commercial organizations, and others), applications (ordering and scheduling, sample collection, manufacturing, logistics, and patient verification and treatment follow-up), regulatory certifications / accreditations (21 CFR Part 11, CLIA, FACT-JACIE, GAMP 5, GDPR, HIPAA, and others), and key support services offered (customization, installation / implementation, maintenance, training / technical support, upgradation, validation and testing, and others).

Chapter 5 features an insightful competitiveness analysis of the software solutions providers based on various parameters, such as number of software systems offered, affiliated modes of deployment, scale of management, end users, applications, regulatory certifications / accreditations, support services offered, and key platform specifications and benefits. In the chapter, stakeholder entities have been plotted on a 2X2 matrix, having a company's Supplier Power (based on its employee base and years of experience in the industry) and Company Competitiveness as the two axes.

Chapter 6 includes elaborate profiles of companies that are currently offering core supply chain management software systems, such as EMS, IMS, LIMS, LMS, PMS, QMS, and TTS (shortlisted on the basis of company competitiveness analysis scores); each profile features an overview of the company, its financial information (if available), and a detailed description of the platform(s). Each profile also includes a list of recent developments, highlighting key achievements, partnership activity and the likely strategies that may be adopted by these players to fuel growth in the foreseen future.

Chapter 7 presents a brief introduction to COPs, along with insights into their key functions and implementation strategies, while also considering their strategic position and connectivity with other adjacent systems within the entire cell and advanced therapies supply chain. Further, the chapter includes a brief discussion on the growing popularity of COP on the social media platform, Twitter, and presents a snapshot of how the public opinion about such technological solutions has evolved in the period 2014-2018. In addition, the chapter features detailed profiles of all the industry players that are currently offering COPs for supply chain management. For each of these companies, we have presented detailed profiles, featuring an overview of the company, its financial information (if available), and a detailed description of the platform(s). Each profile also includes a list of recent developments, highlighting key achievements, partnership activity and the likely strategies that may be adopted by these players to fuel growth in the foreseen future.

Chapter 8 provides information on funding instances and investments that have been made within the cell and advanced therapies supply chain management market. The chapter includes details on various types of investments (such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings) received by companies between 2014 and Q3 2019, highlighting the growing interest of the venture capital community and other strategic investors in this domain.

Chapter 9 features an elaborate discussion and analysis of partnerships / collaborations that have been established in the domain in the period between 2014 and Q3 2019. It includes a brief description of various types of partnership models (such as software licensing agreements, mergers and acquisitions, product development agreements, product integration agreements, distribution agreements, asset purchase agreements, and others) that have been employed by stakeholders within this domain. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances in this industry. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 10 presents a detailed analysis of platform utilization use cases where the aforementioned software systems were leveraged by various stakeholders in the domain, in the period between 2014 and Q3 2019. It includes a brief discussion on the ways in which companies have implemented such software solutions to improve / optimize various supply chain-related processes of cell and advanced therapies.

Chapter 11 provides a qualitative assessment of the current and long-term needs of different stakeholders (patients, healthcare providers, collection centers, manufacturers, logistics service providers and regulators / payers) involved in the cell and advanced therapies supply chain. It also presents a summary of the diverse needs and areas of concern, along with our opinion (based on past and prevalent trends) on how the industry is preparing to address the aforementioned issues.

Chapter 12 presents a detailed review of the cell and advanced therapies supply chain, offering insights on the processes associated with various stages, such as donor eligibility assessment, sample collection, manufacturing, logistics, and patient verification and treatment follow-up, along with information on cost requirements and existing opportunities for improvement in the supply chain management practices.

Chapter 13 features an insightful analysis, highlighting the cost saving potential across various processes of the cell and advanced therapies supply chain that can be brought about by the implementation of bespoke and integrated technological solutions / software systems.

Chapter 14 features a comprehensive market forecast, highlighting the future potential of the supply chain management software solutions market till 2030, based on multiple parameters, such as number of cell and advanced therapies in development, expected pricing, likely adoption rates, and cost saving opportunity from different software systems. In addition, we have provided the likely distribution of the current and forecasted opportunity across [A] different software systems (COP, EMS, IMS, LIMS, LMS, PMS, QMS, and TTS), [B] applications (donor eligibility assessment, sample collection, manufacturing, logistics, and patient verification and treatment follow-up), [C] modes of deployment (cloud and on-premises), [D] end users (biobanks, cell therapy labs, hospitals, research institutes, and commercial organizations), and [E] key geographical regions (North America, Europe and Asia-Pacific). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry's evolution.

Chapter 15 is a collection of executive insights of the discussions that were held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Bryan Poltilove (Vice President and General Manager, Thermo Fisher Scientific), Jacqueline Barry (Chief Clinical Officer, Cell and Gene Therapy Catapult), Jill Maddux (Director, Cell and Gene Therapy Product Strategy, McKesson) and Divya Iyer (Senior Director, Corporate Strategy and Business Development, McKesson), and Martin Lamb (Chief Business Officer, TrakCel)

Chapter 16 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 17 is an appendix, which provides a comprehensive list of technological solutions / software systems that are being used to effectively manage and streamline the supply chain processes of the overall healthcare industry.

Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 19 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Context and Background
  • 3.2. An Introduction to Cell and Advanced Therapies
    • 3.2.1. Classification of Advanced Therapy Medicinal Products
    • 3.2.2. Current Market Landscape
  • 3.3. Cell and Advanced Therapies Supply Chain
    • 3.3.1. Key Processes
      • 3.3.1.1. Donor Eligibility Assessment
      • 3.3.1.2. Sample Collection
      • 3.3.1.3. Manufacturing
      • 3.3.1.4. Logistics
      • 3.3.1.5. Patient Verification and Treatment Follow-up
    • 3.3.2. Challenges Associated with the Cell and Advanced Therapies Supply Chain
      • 3.3.2.1. Process Standardization
      • 3.3.2.2. Process Qualification
      • 3.3.2.3. Chain of Custody Documentation
      • 3.3.2.4. Capacity Scheduling and Resource Utilization
      • 3.3.2.5. Packaging and Shipping Qualification
      • 3.3.2.6. Validation of Storage Containers
  • 3.4. Software Solutions for Cell and Advanced Therapies Supply Chain Management
    • 3.4.1. Cell Orchestration Platform
    • 3.4.2. Enterprise Manufacturing System
    • 3.4.3. Inventory Management System
    • 3.4.4. Laboratory Information Management System
    • 3.4.5. Logistics Management System
    • 3.4.6. Patient Management System
    • 3.4.7. Quality Management System
    • 3.4.8. Tracking and Tracing System
  • 3.5. Growth Drivers and Roadblocks
  • 3.6. Emergence of Digital Technologies in Supply Chain Management
    • 3.6.1. Blockchain Technology
    • 3.6.2. Internet of Things
    • 3.6.3. Augmented Reality
    • 3.6.4. Big Data Analytics
    • 3.6.5. Artificial Intelligence

4. CURRENT MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Cell and Advanced Therapies Supply Chain Management: Overall Market Landscape
    • 4.2.1. Analysis by Type of Software Solution
    • 4.2.2. Analysis by Key Specification and Benefit
    • 4.3.3. Analysis by Application
    • 4.3.4. Analysis by End User
    • 4.3.5. Analysis by Mode of Deployment
    • 4.3.6. Analysis by Scale of Management
    • 4.3.7. Analysis by Regulatory Certifications / Accreditations
  • 4.3. Cell and Advanced Therapies Supply Chain Management: Developer Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Location of Headquarters
    • 4.2.3. Analysis by Size of Company
    • 4.3.4. Analysis by Support Services Offered
    • 4.3.5. Leading Developers: Analysis by Number of Software Solutions

5. COMPANY COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Methodology
  • 5.3. Assumptions and Key Parameters
  • 5.4. Competitiveness Analysis: Overview of Supply Chain Management Software Solution Providers
    • 5.4.1. Small-sized Companies
    • 5.4.2. Mid-sized Companies
    • 5.4.3. Large Companies

6. CORE SUPPLY CHAIN MANAGEMENT SOFTWARE SOLUTIONS: COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Brooks Life Sciences
    • 6.2.1. Company Overview
    • 6.2.2. Financial Information
    • 6.2.3. BiobankPro®: Software Description
    • 6.2.4. Recent Developments and Future Outlook
  • 6.3. Cryoport
    • 6.3.1. Company Overview
    • 6.3.2. Financial Information
    • 6.3.3. Cryoportal®: Software Description
    • 6.3.4. Recent Developments and Future Outlook
  • 6.4. MasterControl
    • 6.4.1. Company Overview
    • 6.4.2. MasterControl Platform™: Software Description
    • 6.4.3. Recent Developments and Future Outlook
  • 6.5. SAP
    • 6.5.1. Company Overview
    • 6.5.2. Financial Information
    • 6.5.3. SAP S/4HANA®: Software Description
    • 6.5.4. Recent Development and Future Outlook
  • 6.6. Savsu Technologies
    • 6.6.1. Company Overview
    • 6.6.2. Financial Information
    • 6.6.3. evo® Cold Chain 2.0™: Software Description
    • 6.6.4. Recent Development and Future Outlook
  • 6.7. TraceLink
    • 6.7.1. Company Overview
    • 6.7.2. Financial Information
    • 6.7.3. Digital Supply Chain Platform: Software Description
    • 6.7.4. Recent Developments and Future Outlook

7. CELL ORCHESTRATION PLATFORMS: EMERGING TRENDS AND PROFILES OF KEY PLAYERS

  • 7.1. Chapter Overview
  • 7.2. Supply Chain Orchestration Platforms
    • 7.2.1. Key Functions of Supply Chain Orchestration Platforms
    • 7.2.2. Advantages of Supply Chain Orchestration Platforms
    • 7.2.3. Supply Chain Orchestration Platform Implementation Strategies
      • 7.2.3.1. Building the Required Foundation
      • 7.2.3.2. Incorporating an Appropriate Scheduling System
      • 7.2.3.3. Integration with Core Systems / Processes
  • 7.3. Supply Chain Orchestration Platform: Trends on Twitter
    • 7.3.1. Scope and Methodology
    • 7.3.2. Historical Trends in Volume of Tweets
    • 7.3.3. Popular Keywords
  • 7.4. Key Industry Players
    • 7.4.1. Be The Match BioTherapies®
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial Information
      • 7.4.1.3. MatchSource®: Software Description
      • 7.4.1.4. Recent Developments and Future Outlook
    • 7.4.2. Clarkston Consulting
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Cell Therapy Orchestration Platform: Software Description
      • 7.4.2.3. Recent Developments and Future Outlook
    • 7.4.3. Haemonetics
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Information
      • 7.4.3.3. EdgeCell®: Software Description
      • 7.4.3.4. Recent Developments and Future Outlook
    • 7.4.4. Hypertrust Patient Data Care
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Hypertrust X-Chain: Software Description
      • 7.4.4.3. Recent Developments and Future Outlook
    • 7.4.5. Lykan Bioscience
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Unnamed Platform: Software Description
      • 7.4.5.3. Recent Developments and Future Outlook
    • 7.4.6. MAK-SYSTEM
      • 7.4.6.1. Company Overview
      • 7.4.6.2. T.C.S.: Software Description
      • 7.4.6.3. Recent Developments and Future Outlook
    • 7.4.7. sedApta Group
      • 7.4.7.1. Company Overview
      • 7.4.7.2. O.S.A.: Software Description
      • 7.4.7.3. Recent Developments and Future Outlook
    • 7.4.8. Stafa Cellular Therapy
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Stafa Cellular Therapy Lab: Software Description
      • 7.4.8.3. Recent Developments and Future Outlook
    • 7.4.9. Title 21 Health Solutions
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Cell Therapy Software: Software Description
      • 7.4.9.3. Recent Developments and Future Outlook
    • 7.4.10. TrakCel
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial Information
      • 7.4.10.3. TrakCel™ Cell Orchestration Platform: Software Description
      • 7.4.10.4. Recent Developments and Future Outlook
    • 7.4.11. Vineti
      • 7.4.11.1. Company Overview
      • 7.4.11.2. Financial Information
      • 7.4.11.3. Personalized Therapy Management Software: Software Description
      • 7.4.11.4. Recent Developments and Future Outlook

8. FUNDING AND INVESTMENT ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Types of Funding
  • 8.3. Cell and Advanced Therapies Supply Chain Management: Recent Funding Instances
    • 8.3.1. Analysis by Number of Funding Instances
    • 8.3.2. Analysis by Amount Invested
    • 8.3.3. Analysis by Type of Funding
    • 8.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Software Solutions
    • 8.3.5. Most Active Players: Analysis by Amount Invested
    • 8.3.6. Most Active Investors: Analysis by Participation
    • 8.3.7. Geographical Analysis by Amount Invested
  • 8.4. Concluding Remarks

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Cell and Advanced Therapies Supply Chain Management: Recent Collaborations and Partnerships
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Partner's Focus Area
    • 9.3.4. Analysis by Type of Software Solution
    • 9.3.5. Most Active Players: Analysis by Number of Partnerships
    • 9.3.6. Analysis by Regions
      • 9.3.6.1. Most Active Players: Regional Analysis by Number of Partnerships
      • 9.3.6.2. Intercontinental and Intracontinental Agreements

10. PLATFORM UTILIZATION USE CASES

  • 10.1. Chapter Overview
  • 10.2. Cell and Advanced Therapies Supply Chain Management: Recent Platform Utilization Use Cases
    • 10.2.1. Analysis by Year of Utilization
    • 10.2.2. Analysis by User's Focus Area
    • 10.2.3. Analysis by Type of Software Solution
    • 10.2.4. Most Active Players: Analysis by Number of Utilization Instances
    • 10.2.5. Most Active Players: Regional Analysis by Number of Utilization Instances

11. VALUE CHAIN ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Cell and Advanced Therapies Value Chain
  • 11.2. Cell and Advanced Therapies Value Chain: Cost Distribution
    • 11.3.1. Donor Eligibility Assessment
    • 11.3.2. Sample Collection
    • 11.3.3. Manufacturing
    • 11.3.4. Logistics
    • 11.3.5. Patient Verification and Treatment Follow-up

12. STAKEHOLDER NEEDS ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Cell and Advanced Therapies Supply Chain Management: Needs of Different Stakeholders
    • 12.2.1. Comparison of Stakeholder Needs

13. COST SAVINGS ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Key Assumptions and Methodology
  • 13.3. Overall Cost Saving Potential of Supply Chain Management Software Solutions, 2019-2030
    • 13.3.1. Cost Saving Potential in Donor Eligibility Assessment, 2019-2030
    • 13.3.2. Cost Saving Potential in Sample Collection, 2019-2030
    • 13.3.3. Cost Saving Potential in Manufacturing, 2019-2030
    • 13.3.4. Cost Saving Potential in Logistics, 2019-2030
    • 13.3.5. Cost Saving Potential in Patient Verification and Treatment Follow-up, 2019-2030

14. MARKET FORECAST

  • 14.1. Chapter Overview
  • 14.2. Key Assumptions and Forecast Methodology
  • 14.3. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, 2019-2030
    • 14.3.1. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application
      • 14.3.1.1. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, 2019-2030
      • 14.3.1.2. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, 2019-2030
      • 14.3.1.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, 2019-2030
      • 14.3.1.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, 2019-2030
      • 14.3.1.5. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030
    • 14.3.2. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User
      • 14.3.2.1. Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, 2019-2030
      • 14.3.2.2. Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs, 2019-2030
      • 14.3.2.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals, 2019-2030
      • 14.3.2.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, 2019-2030
      • 14.3.2.5. Cell and Advanced Therapies Supply Chain Management Solutions Market for Commercial Organizations, 2019-2030
    • 14.3.3. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution
      • 14.3.3.1. Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
      • 14.3.3.2. Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
      • 14.3.3.3. Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
      • 14.3.3.4. Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
      • 14.3.3.5. Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
      • 14.3.3.6. Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
      • 14.3.3.7. Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
    • 14.3.4. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment
      • 14.3.4.1. Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, 2019-2030
      • 14.3.4.2. Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, 2019-2030
    • 14.3.5. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography
      • 14.3.5.1. Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, 2019-2030
      • 14.3.5.2. Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, 2019-2030
      • 14.3.5.2. Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, 2019-2030
  • 14.4. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Type of Software Solution and Mode of Deployment
    • 14.4.1. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, 2019-2030
      • 14.4.1.1. Patient Management Systems Market for Donor Eligibility Assessment, 2019-2030
        • 14.4.1.1.1. Patient Management Systems Market for Donor Eligibility Assessment: Cloud-based Solutions, 2019-2030
        • 14.4.1.1.2. Patient Management Systems Market for Donor Eligibility Assessment: On-premises Solutions, 2019-2030
      • 14.4.1.2. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment, 2019-2030
        • 14.4.1.2.1. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: Cloud-based Solutions, 2019-2030
        • 14.4.1.2.2. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: On-premises Solutions, 2019-2030
    • 14.4.2. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, 2019-2030
      • 14.4.2.1. Inventory Management Systems Market for Sample Collection, 2019-2030
        • 14.4.2.1.1. Inventory Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030
        • 14.4.2.1.2. Inventory Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030
      • 14.4.2.2. Laboratory Information Management Systems Market for Sample Collection, 2019-2030
        • 14.4.2.2.1. Laboratory Information Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030
        • 14.4.2.2.2. Laboratory Information Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030
      • 14.4.2.3. Logistics Management Systems Market for Sample Collection, 2019-2030
        • 14.4.2.3.1. Logistics Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030
        • 14.4.2.3.2. Logistics Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030
      • 14.4.2.4. Quality Management Systems Market for Sample Collection, 2019-2030
        • 14.4.2.4.1. Quality Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030
        • 14.4.2.4.2. Quality Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030
      • 14.4.2.5. Supply Chain Orchestration Platforms Market for Sample Collection, 2019-2030
        • 14.4.2.5.1. Supply Chain Orchestration Platforms Market for Sample Collection: Cloud-based Solutions, 2019-2030
        • 14.4.2.5.2. Supply Chain Orchestration Platforms Market for Sample Collection: On-premises Solutions, 2019-2030
    • 14.4.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, 2019-2030
      • 14.4.3.1. Enterprise Manufacturing Systems Market for Manufacturing, 2019-2030
        • 14.4.3.1.1. Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
        • 14.4.3.1.2. Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, 2019-2030
      • 14.4.3.2. Inventory Management Systems Market for Manufacturing, 2019-2030
        • 14.4.3.2.1. Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
        • 14.4.3.2.2. Inventory Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030
      • 14.4.3.3. Laboratory Information Management Systems Market for Manufacturing, 2019-2030
        • 14.4.3.3.1. Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
        • 14.4.3.3.2. Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030
      • 14.4.3.4. Quality Management Systems Market for Manufacturing, 2019-2030
        • 14.4.3.4.1. Quality Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
        • 14.4.3.4.2. Quality Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030
      • 14.4.3.5. Supply Chain Orchestration Platforms Market for Manufacturing, 2019-2030
        • 14.4.3.5.1. Supply Chain Orchestration Platforms Market for Manufacturing: Cloud-based Solutions, 2019-2030
        • 14.4.3.5.2. Supply Chain Orchestration Platforms Market for Manufacturing: On-premises Solutions, 2019-2030
    • 14.4.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, 2019-2030
      • 14.4.4.1. Logistics Management Systems Market for Logistics, 2019-2030
        • 14.4.4.1.1. Logistics Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030
        • 14.4.4.1.2. Logistics Management Systems Market for Logistics: On-premises Solutions, 2019-2030
      • 14.4.4.2. Supply Chain Orchestration Platforms Market for Logistics, 2019-2030
        • 14.4.4.2.1. Supply Chain Orchestration Platforms Market for Logistics: Cloud-based Solutions, 2019-2030
        • 14.4.4.2.2. Supply Chain Orchestration Platforms Market for Logistics: On-premises Solutions, 2019-2030
    • 14.4.5. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030
      • 14.4.5.1. Patient Management Systems Market for Patient Verification and Treatment Follow-up, 2019-2030
        • 14.4.5.1.1. Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030
        • 14.4.5.1.2. Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030
      • 14.4.5.2. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up, 2019-2030
        • 14.4.5.2.1. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030
        • 14.4.5.2.2. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030

15. EXECUTIVE INSIGHTS

  • 15.1. Chapter Overview
  • 15.2. Thermo Fisher Scientific
    • 15.2.1. Company Snapshot
    • 15.2.2. Interview Transcript: Bryan Poltilove, Vice President and General Manager
  • 15.3. Cell and Gene Therapy Catapult
    • 15.3.1. Company Snapshot
    • 15.3.2. Interview Transcript: Jacqueline Barry, Chief Clinical Officer
  • 15.4. McKesson
    • 15.4.1. Company Snapshot
    • 15.4.2. Interview Transcript: Jill Maddux, Director, Cell and Gene Therapy Product Strategy, and Divya Iyer, Senior Director, Corporate Strategy and Business Development
  • 15.5. TrakCel
    • 15.5.1. Company Snapshot
    • 15.5.2. Interview Transcript: Martin Lamb, Chief Business Officer

16. CONCLUDING REMARKS

  • 16.1. Chapter Overview
  • 16.2. Key Takeaways

17. APPENDIX 1: LIST OF ADDITIONAL SUPPLY CHAIN MANAGEMENT SOFTWARE SOLUTIONS

18. APPENDIX 2: TABULATED DATA

19. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

  • Figure 3.1. Classification of Advanced Therapy Medicinal Products
  • Figure 3.2. Market Access Landscape of Key Cell and Advanced Therapies across Different Geographies
  • Figure 3.3. Key Processes of Cell and Advanced Therapies Supply Chain
  • Figure 3.4. Responsibilities of Stakeholders Involved in Cell and Advanced Therapies Supply Chain
  • Figure 3.4. Key Steps Involved in the Manufacturing of Cell and Advanced Therapies
  • Figure 3.5. Keys Steps Involved in Logistics Operations of Autologous Therapies
  • Figure 3.6. Comparison of Logistics Processes for Autologous and Allogeneic Therapies
  • Figure 3.7. Key Challenges Related to Cell and Advanced Therapies Supply Chain
  • Figure 3.8. Key Considerations for Transportation of Cell and Advanced Therapies
  • Figure 3.9. Temperature Variations across Cryogenic Vessels / Dewars for Storage of Cell and Advanced Therapies
  • Figure 3.10. Recommendations for Process Qualification of Cell and Advanced Therapies
  • Figure 3.11. Overview of Supply Chain Orchestration Platforms
  • Figure 3.12. Functions of Key Software Solutions for Cell and Advanced Therapies Supply Chain Management
  • Figure 3.13. Growth Drivers and Roadblocks to Software Solutions in Cell and Advanced Therapies Supply Chain
  • Figure 4.1. Cell and Advanced Therapies Supply Chain Management: Distribution by Type of Software Solution
  • Figure 4.2. Cell and Advanced Therapies Supply Chain Management: Distribution by Key Specifications and Benefits
  • Figure 4.3. Cell and Advanced Therapies Supply Chain Management: Distribution by Application
  • Figure 4.4. Cell and Advanced Therapies Supply Chain Management: Distribution by End User
  • Figure 4.5. Cell and Advanced Therapies Supply Chain Management: Distribution by Mode of Deployment
  • Figure 4.6. Cell and Advanced Therapies Supply Chain Management: Distribution by Scale of Management
  • Figure 4.7. Cell and Advanced Therapies Supply Chain Management: Distribution by Regulatory Certification / Accreditation
  • Figure 4.8. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Year of Establishment
  • Figure 4.9. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Geographical Location
  • Figure 4.10. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Company Size
  • Figure 4.11. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Services Offered
  • Figure 4.12. Leading Developers: Distribution by Number of Software Solutions
  • Figure 5.1. Competitiveness Analysis of Small-sized Supply Chain Management Software Solutions Providers
  • Figure 5.2. Competitiveness Analysis of Mid-sized Supply Chain Management Software Solutions Providers
  • Figure 5.3. Competitiveness Analysis of Large-sized Supply Chain Management Software Solutions Providers
  • Figure 6.1. Brooks Life Sciences: Net Sales, FY 2014 - H1 2019 (USD Million)
  • Figure 6.2. Cryoport: Net Sales, FY 2014 - H1 2019 (USD Million)
  • Figure 6.3. SAP: Net Sales, FY 2014 - H1 2019 (USD Million)
  • Figure 7.1. Standardization of Tasks by Supply Chain Orchestration Platforms
  • Figure 7.2. Key Functions of Supply Chain Orchestration Platforms
  • Figure 7.3. Advantages of Supply Chain Orchestration Platforms
  • Figure 7.4. Trends on Social Media: Historical Activity on Twitter, 2015-2018
  • Figure 7.5. Trends on Social Media: Popular Keywords
  • Figure 7.6. Be The Match BioTherapies®: Net Sales, FY 2013 - FY 2018 (USD Billion)
  • Figure 8.1. Funding and Investments: Distribution of Companies by Year of Establishment and Type of Funding, 2014-Q3 2019
  • Figure 8.2. Funding and Investments: Distribution of Amount Invested by Focus Area and Type of Funding, 2014-Q3 2019
  • Figure 8.3. Funding and Investments: Cumulative Year-wise Trend, 2014-Q3 2019
  • Figure 8.4. Funding and Investments: Cumulative Amount Invested by Year, 2014-Q3 2019 (USD Million)
  • Figure 8.5. Funding and Investments: Distribution by Type of Funding
  • Figure 8.6. Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
  • Figure 8.7. Popular Software Solutions: Distribution by Number of Funding Instances
  • Figure 8.8. Popular Software Solutions: Distribution by Amount Invested (USD Million)
  • Figure 8.9. Funding Instances: Year-wise Trend of Amount Invested across Different Software Solutions, 2014-Q3 2019 (USD Million)
  • Figure 8.10. Most Active Players: Distribution by Number of Instances
  • Figure 8.11. Most Active Players: Distribution by Capital Amount Raised (USD Million)
  • Figure 8.12. Most Active Investors: Distribution by Number of Instances
  • Figure 8.13. Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
  • Figure 8.14. Funding and Investment Summary
  • Figure 9.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-Q3 2019
  • Figure 9.2. Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3. Partnerships and Collaborations: Year-wise Trend by Type of Partnership
  • Figure 9.4. Partnerships and Collaborations: Distribution by Partner's Focus Area
  • Figure 9.5. Partnerships and Collaborations: Distribution by Type of Software Solution
  • Figure 9.6. Partnerships and Collaborations: Year-wise Trend by Type of Software Solution
  • Figure 9.7. Most Active Players: Distribution by Number of Partnerships
  • Figure 9.8. Most Active Players: Regional Distribution by Number of Partnerships
  • Figure 9.9. Partnerships and Collaborations: Regional Distribution (Intercontinental and Intracontinental Agreements)
  • Figure 10.1. Platform Utilization Use Cases: Cumulative Year-wise Trend, 2014-Q3 2019
  • Figure 10.2. Platform Utilization Use Cases: Distribution by User's Focus Area
  • Figure 10.3. Platform Utilization Use Cases: Distribution by Type of Software Solution
  • Figure 10.4. Platform Utilization Use Cases: Year-wise Trend by Type of Software Solution
  • Figure 10.5. Most Active Players: Distribution by Number of Utilization Instances
  • Figure 10.6. Most Active Players: Regional Distribution by Number of Utilization Instances
  • Figure 11.1. Key Processes of Cell and Advanced Therapies Value Chain
  • Figure 11.2. Cell and Advanced Therapies Value Chain: Cost Distribution
  • Figure 11.3. Cell and Advanced Therapies Value Chain: Donor Eligibility Assessment
  • Figure 11.4. Cell and Advanced Therapies Value Chain: Sample Collection
  • Figure 11.5. Cell and Advanced Therapies Value Chain: Manufacturing
  • Figure 11.6. Cell and Advanced Therapies Value Chain: Logistics
  • Figure 11.7. Cell and Advanced Therapies Value Chain: Patient Verification and Treatment Follow-up
  • Figure 12.1. Cell and Advanced Therapies Supply Chain Management: Stakeholders Needs Analysis
  • Figure 12.2. Comparison of Stakeholder Needs
  • Figure 13.1. Overall Cost Saving Potential of Supply Chain Management: Likely Scenarios
  • Figure 13.2. Overall Cost Saving Potential of Supply Chain Management Software Solutions, 2019-2030 (USD Million)
  • Figure 13.3. Cost Saving Potential in Donor Eligibility Assessment, 2019-2030 (USD Million)
  • Figure 13.4. Cost Saving Potential in Sample Collection, 2019-2030 (USD Million)
  • Figure 13.5. Cost Saving Potential in Manufacturing, 2019-2030 (USD Million)
  • Figure 13.6. Cost Saving Potential in Logistics, 2019-2030 (USD Million)
  • Figure 13.7. Cost Saving Potential in Patient Verification and Treatment Follow-up, 2019-2030 (USD Million)
  • Figure 14.1. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, 2019-2030 (USD Million)
  • Figure 14.2. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, 2019-2030 (USD Million)
  • Figure 14.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, 2019-2030 (USD Million)
  • Figure 14.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, 2019-2030 (USD Million)
  • Figure 14.5. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, 2019-2030 (USD Million)
  • Figure 14.6. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, 2019-2030 (USD Million)
  • Figure 14.7. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030 (USD Million)
  • Figure 14.8. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User, 2019-2030 (USD Million)
  • Figure 14.9. Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, 2019-2030 (USD Million)
  • Figure 14.10. Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs, 2019-2030 (USD Million)
  • Figure 14.11. Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals, 2019-2030 (USD Million)
  • Figure 14.12. Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, 2019-2030 (USD Million)
  • Figure 14.13. Cell and Advanced Therapies Supply Chain Management Solutions Market for Commercial Organizations, 2019-2030 (USD Million)
  • Figure 14.14. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution, 2019-2030 (USD Million)
  • Figure 14.15. Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
  • Figure 14.16. Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
  • Figure 14.17. Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
  • Figure 14.18. Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
  • Figure 14.19. Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
  • Figure 14.20. Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
  • Figure 14.21. Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
  • Figure 14.22. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment, 2019-2030 (USD Million)
  • Figure 14.23. Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, 2019-2030 (USD Million)
  • Figure 14.24. Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, 2019-2030 (USD Million)
  • Figure 14.25. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography, 2019-2030 (USD Million)
  • Figure 14.26. Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, 2019-2030 (USD Million)
  • Figure 14.27. Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, 2019-2030 (USD Million)
  • Figure 14.28. Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, 2019-2030 (USD Million)
  • Figure 14.29. Patient Management Systems Market for Donor Eligibility Assessment, 2019-2030 (USD Million)
  • Figure 14.30. Patient Management Systems Market for Donor Eligibility Assessment: Cloud-based Solutions, 2019-2030 (USD Million)
  • Figure 14.31. Patient Management Systems Market for Donor Eligibility Assessment: On-premises Solutions, 2019-2030 (USD Million)
  • Figure 14.32. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment, 2019-2030 (USD Million)
  • Figure 14.33. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: Cloud-based Solutions, 2019-2030 (USD Million)
  • Figure 14.34. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: On-premises Solutions, 2019-2030 (USD Million)
  • Figure 14.35. Inventory Management Systems Market for Sample Collection, 2019-2030 (USD Million)
  • Figure 14.36. Inventory Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030 (USD Million)
  • Figure 14.37. Inventory Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030 (USD Million)
  • Figure 14.38. Laboratory Information Management Systems Market for Sample Collection, 2019-2030 (USD Million)
  • Figure 14.39. Laboratory Information Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030 (USD Million)
  • Figure 14.40. Laboratory Information Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030 (USD Million)
  • Figure 14.41. Logistics Management Systems Market for Sample Collection, 2019-2030 (USD Million)
  • Figure 14.42. Logistics Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030 (USD Million)
  • Figure 14.43. Logistics Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030 (USD Million)
  • Figure 14.44. Quality Management Systems Market for Sample Collection, 2019-2030 (USD Million)
  • Figure 14.45. Quality Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030 (USD Million)
  • Figure 14.46. Quality Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030 (USD Million)
  • Figure 14.47. Supply Chain Orchestration Platforms Market for Sample Collection, 2019-2030 (USD Million)
  • Figure 14.48. Supply Chain Orchestration Platforms Market for Sample Collection: Cloud-based Solutions, 2019-2030
  • Figure 14.49. Supply Chain Orchestration Platforms Market for Sample Collection: On-premises Solutions, 2019-2030
  • Figure 14.50. Enterprise Manufacturing Systems Market for Manufacturing, 2019-2030 (USD Million)
  • Figure 14.51. Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 (USD Million)
  • Figure 14.52. Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, 2019-2030 (USD Million)
  • Figure 14.53. Inventory Management Systems Market for Manufacturing, 2019-2030 (USD Million)
  • Figure 14.54. Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 (USD Million)
  • Figure 14.55. Inventory Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030 (USD Million)
  • Figure 14.56. Laboratory Information Management Systems Market for Manufacturing, 2019-2030 (USD Million)
  • Figure 14.57. Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 (USD Million)
  • Figure 14.58. Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030 (USD Million)
  • Figure 14.59. Quality Management Systems Market for Manufacturing, 2019-2030 (USD Million)
  • Figure 14.60. Quality Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 (USD Million)
  • Figure 14.61. Quality Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030 (USD Million)
  • Figure 14.62. Supply Chain Orchestration Platforms Market for Manufacturing, 2019-2030 (USD Million)
  • Figure 14.63. Supply Chain Orchestration Platforms Market for Manufacturing: Cloud-based Solutions, 2019-2030
  • Figure 14.64. Supply Chain Orchestration Platforms Market for Manufacturing: On-premises Solutions, 2019-2030
  • Figure 14.65. Logistics Management Systems Market for Logistics, 2019-2030 (USD Million)
  • Figure 14.66. Logistics Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030 (USD Million)
  • Figure 14.67. Logistics Management Systems Market for Logistics: On-premises Solutions, 2019-2030 (USD Million)
  • Figure 14.68. Supply Chain Orchestration Platforms Market for Logistics, 2019-2030 (USD Million)
  • Figure 14.69. Supply Chain Orchestration Platforms Market for Logistics: Cloud-based Solutions, 2019-2030
  • Figure 14.70. Supply Chain Orchestration Platforms Market for Logistics: On-premises Solutions, 2019-2030
  • Figure 14.71. Patient Management Systems Market for Patient Verification and Treatment Follow-up, 2019-2030 (USD Million)
  • Figure 14.72. Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030 (USD Million)
  • Figure 14.73. Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030 (USD Million)
  • Figure 14.74. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up, 2019-2030 (USD Million)
  • Figure 14.75. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030 (USD Million)
  • Figure 14.76. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030 (USD Million)

List of Tables

  • Table 3.1. Applications of Cell and Advanced Therapies
  • Table 3.2. Differences between Cell and Advanced Therapies and Biotechnology Products
  • Table 3.3. Cell and Advanced Therapies: Commercialized Products
  • Table 4.1. Cell and Advanced Therapies Supply Chain Management: Information on Type of Software Solution
  • Table 4.2. Cell and Advanced Therapies Supply Chain Management: Information on Key Software Specifications and Benefits
  • Table 4.3. Cell and Advanced Therapies Supply Chain Management: Information on Key Applications and End Users
  • Table 4.4. Cell and Advanced Therapies Supply Chain Management: Information on Mode of Deployment, Scale of Management and Key Regulatory Certifications / Accreditations
  • Table 4.5. Cell and Advanced Therapies Supply Chain Management: Developer Overview
  • Table 4.6. Cell and Advanced Therapies Supply Chain Management: Information on key Support Services Offered
  • Table 6.1. Brooks Life Sciences: Key Highlights
  • Table 6.2. Brooks Life Sciences: Key Characteristics of BiobankPro®
  • Table 6.3. Brooks Life Sciences: Recent Developments and Future Outlook
  • Table 6.4. Cryoport: Key Highlights
  • Table 6.5. Cryoport: Key Characteristics of Cryoportal®
  • Table 6.6. Cryoport: Recent Developments and Future Outlook
  • Table 6.7. MasterControl: Key Highlights
  • Table 6.8. MasterControl: Key Characteristics of MasterControl Platform™
  • Table 6.9. MasterControl: Recent Developments and Future Outlook
  • Table 6.10. SAP: Key Highlights
  • Table 6.11. SAP: Key Characteristics of SAP S/4HANA®
  • Table 6.12. SAP: Recent Developments and Future Outlook
  • Table 6.13. Savsu Technologies: Key Highlights
  • Table 6.14. Savsu Technologies: Funding Instances
  • Table 6.15. Savsu Technologies: Key Characteristics of evo® Cold Chain 2.0™
  • Table 6.16. Savsu Technologies: Recent Developments and Future Outlook
  • Table 6.17. TraceLink: Key Highlights
  • Table 6.18. TraceLink: Funding Instances
  • Table 6.19. TraceLink: Key Characteristics of Digital Supply Chain Platform
  • Table 6.20. TraceLink: Recent Developments and Future Outlook
  • Table 7.1. Be The Match BioTherapies®: Key Highlights
  • Table 7.2. Be The Match BioTherapies®: Key Characteristics of MatchSource®
  • Table 7.3. Be The Match BioTherapies®: Recent Developments and Future Outlook
  • Table 7.4. Clarkston Consulting: Key Highlights
  • Table 7.5. Clarkston Consulting: Key Characteristics of Cell Therapy Orchestration Platform
  • Table 7.6. Clarkston Consulting: Recent Developments and Future Outlook
  • Table 7.7. Haemonetics: Key Highlights
  • Table 7.8. Haemonetics: Key Characteristics of EdgeCell®
  • Table 7.9. Haemonetics: Recent Developments and Future Outlook
  • Table 7.10. Hypertrust Patient Data Care: Key Highlights
  • Table 7.11. Hypertrust Patient Data Care: Key Characteristics of Hypertrust X-Chain
  • Table 7.12. Hypertrust Patient Data Care: Recent Developments and Future Outlook
  • Table 7.13. Lykan Bioscience: Key Highlights
  • Table 7.14. Lykan Bioscience: Key Characteristics of Unnamed Cell Orchestration Platform
  • Table 7.15. Lykan Bioscience: Recent Developments and Future Outlook
  • Table 7.16. MAK-SYSTEM: Key Highlights
  • Table 7.17. MAK-SYSTEM: Key Characteristics of T.C.S.
  • Table 7.18. MAK-SYSTEM: Recent Developments and Future Outlook
  • Table 7.19. sedApta Group: Key Highlights
  • Table 7.20. sedApta Group: Key Characteristics of O.S.A.
  • Table 7.21. sedApta Group: Recent Developments and Future Outlook
  • Table 7.22. Stafa Cellular Therapy: Key Highlights
  • Table 7.23. Stafa Cellular Therapy: Key Characteristics of Stafa Cellular Therapy Lab
  • Table 7.24. Stafa Cellular Therapy: Recent Developments and Future Outlook
  • Table 7.25. Title 21 Health Solutions: Key Highlights
  • Table 7.26. Title 21 Health Solutions: Key Characteristics of Cell Therapy Software
  • Table 7.27. Title 21 Health Solutions: Recent Developments and Future Outlook
  • Table 7.28. TrakCel: Key Highlights
  • Table 7.29. TrakCel: Funding Instances
  • Table 7.20. TrakCel: Key Characteristics of TrakCel™ Cell Orchestration Platform
  • Table 7.31. TrakCel: Recent Developments and Future Outlook
  • Table 7.32. Vineti: Key Highlights
  • Table 7.33. Vineti: Funding Instances
  • Table 7.34. Vineti: Key Characteristics of Personalized Therapy Management Software
  • Table 7.35. Vineti: Recent Developments and Future Outlook
  • Table 8.1. Cell and Advanced Therapies Supply Chain Management: List of Funding Instances, 2014-Q3 2019
  • Table 8.2. Cell and Advanced Therapies Supply Chain Management: Summary of Investments
  • Table 9.1. Cell and Advanced Therapies Supply Chain Management: List of Partnerships, 2014-Q3 2019
  • Table 9.2. Most Active Players: Regional Distribution by Number of Partnerships
  • Table 10.1. Cell and Advanced Therapies Supply Chain Management: List of Platform Utilization Use Cases, 2014-Q3 2019
  • Table 15.1. Thermo Fisher Scientific: Key Highlights
  • Table 15.2. Cell and Gene Therapy Catapult: Key Highlights
  • Table 15.3. McKesson: Key Highlights
  • Table 15.4. TrakCel: Key Highlights
  • Table 16.1. Cell and Advanced Therapies Supply Chain Management: Key Takeaways of the Report
  • Table 17.1. List of Additional Supply Chain Management Software Solutions
  • Table 19.1. Cell and Advanced Therapies Supply Chain Management: Distribution by Type of Software Solution
  • Table 19.2. Cell and Advanced Therapies Supply Chain Management: Distribution by Key Specifications and Benefits
  • Table 19.3. Cell and Advanced Therapies Supply Chain Management: Distribution by Application
  • Table 19.4. Cell and Advanced Therapies Supply Chain Management: Distribution by End User
  • Table 19.5. Cell and Advanced Therapies Supply Chain Management: Distribution by Mode of Deployment
  • Table 19.6. Cell and Advanced Therapies Supply Chain Management: Distribution by Scale of Management
  • Table 19.7. Cell and Advanced Therapies Supply Chain Management: Distribution by Regulatory Certification / Accreditation
  • Table 19.8. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Year of Establishment
  • Table 19.9. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Geographical Location
  • Table 19.10. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Company Size
  • Table 19.11. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Services Offered
  • Table 19.12. Leading Developers: Distribution by Number of Software Solutions
  • Table 19.13. Brooks Life Sciences: Net Sales, FY 2014 - H1 2019 (USD Million)
  • Table 19.14. Cryoport: Net Sales, FY 2014 - H1 2019 (USD Million)
  • Table 19.15. SAP: Net Sales, FY 2014 - H1 2019 (USD Million)
  • Table 19.16. Trends on Social Media: Historical Activity on Twitter, 2015-2018
  • Table 19.17. Be The Match BioTherapies®: Net Sales, FY 2013 - FY 2018 (USD Billion)
  • Table 19.18. Funding and Investments: Distribution of Companies by Year of Establishment and Type of Funding, 2014-Q3 2019
  • Table 19.19. Funding and Investments: Distribution of Amount Invested by Focus Area and Type of Funding, 2014-Q3 2019
  • Table 19.20. Funding and Investments: Cumulative Year-wise Trend, 2014-Q3 2019
  • Table 19.21. Funding and Investments: Cumulative Amount Invested by Year, 2014-Q3 2019 (USD Million)
  • Table 19.22. Funding and Investments: Distribution by Type of Funding
  • Table 19.23. Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
  • Table 19.24. Popular Software Solutions: Distribution by Number of Funding Instances
  • Table 19.25. Popular Software Solutions: Distribution by Amount Invested (USD Million)
  • Table 19.26. Funding Instances: Year-wise Trend of Amount Invested across Different Software Solutions, 2014-Q3 2019 (USD Million)
  • Table 19.27. Most Active Players: Distribution by Number of Instances
  • Table 19.28. Most Active Players: Distribution by Capital Amount Raised (USD Million)
  • Table 19.29. Most Active Investors: Distribution by Number of Instances
  • Table 19.30. Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
  • Table 19.31. Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-Q3 2019
  • Table 19.32. Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 19.33. Partnerships and Collaborations: Year-wise Trend by Type of Partnership
  • Table 19.34. Partnerships and Collaborations: Distribution by Partner's Focus Area
  • Table 19.35. Partnerships and Collaborations: Distribution by Type of Software Solution
  • Table 19.36. Partnerships and Collaborations: Year-wise Trend by Type of Software Solution
  • Table 19.37. Most Active Players: Distribution by Number of Partnerships
  • Table 19.38. Most Active Players: Regional Distribution by Number of Partnerships
  • Table 19.39. Partnerships and Collaborations: Regional Distribution (Intercontinental and Intracontinental Agreements)
  • Table 19.40. Platform Utilization Use Cases: Cumulative Year-wise Trend, 2014-Q3 2019
  • Table 19.41. Platform Utilization Use Cases: Distribution by User's Focus Area
  • Table 19.42. Platform Utilization Use Cases: Distribution by Type of Software Solution
  • Table 19.43. Platform Utilization Use Cases: Year-wise Trend by Type of Software Solution
  • Table 19.44. Most Active Players: Distribution by Number of Utilization Instances
  • Table 19.45. Most Active Players: Regional Distribution by Number of Utilization Instances
  • Table 19.46. Cell and Advanced Therapies Value Chain: Cost Distribution
  • Table 19.47. Overall Cost Saving Potential of Supply Chain Management Software Solutions, 2019-2030 (USD Million)
  • Table 19.48. Cost Saving Potential in Donor Eligibility Assessment, 2019-2030 (USD Million)
  • Table 19.49. Cost Saving Potential in Sample Collection, 2019-2030 (USD Million)
  • Table 19.50. Cost Saving Potential in Manufacturing, 2019-2030 (USD Million)
  • Table 19.51. Cost Saving Potential in Logistics, 2019-2030 (USD Million)
  • Table 19.52. Cost Saving Potential in Patient Verification and Treatment Follow-up, 2019-2030 (USD Million)
  • Table 19.53. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.54. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, Base Scenario, 2019-2030 (USD Million)
  • Table 19.55. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.56. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.57. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Base Scenario, 2019-2030 (USD Million)
  • Table 19.58. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.59. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.60. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, Base Scenario, 2019-2030 (USD Million)
  • Table 19.61. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.62. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.63. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
  • Table 19.64. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.65. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.66. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
  • Table 19.67. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.68. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.69. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, Base Scenario, 2019-2030 (USD Million)
  • Table 19.70. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.71. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.72. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, Base Scenario, 2019-2030 (USD Million)
  • Table 19.73. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.74. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.75. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User, Base Scenario, 2019-2030 (USD Million)
  • Table 19.76. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.77. Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.78. Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, Base Scenario, 2019-2030 (USD Million)
  • Table 19.79. Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.80. Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.81. Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs, Base Scenario, 2019-2030 (USD Million)
  • Table 19.82. Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.83. Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.84. Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals, Base Scenario, 2019-2030 (USD Million)
  • Table 19.85. Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.86. Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.87. Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, Base Scenario, 2019-2030 (USD Million)
  • Table 19.88. Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.89. Cell and Advanced Therapies Supply Chain Management Solutions Market for Commercial Organizations, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.90. Cell and Advanced Therapies Supply Chain Management Solutions Market for Commercial Organizations, Base Scenario, 2019-2030 (USD Million)
  • Table 19.91. Cell and Advanced Therapies Supply Chain Management Solutions Market for Commercial Organizations, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.92. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.93. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution, Base Scenario, 2019-2030 (USD Million)
  • Table 19.94. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.95. Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.96. Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
  • Table 19.97. Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.98. Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.99. Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
  • Table 19.100. Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.101. Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.102. Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
  • Table 19.103. Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.104. Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.105. Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
  • Table 19.106. Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.107. Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.108. Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
  • Table 19.109. Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.110. Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.111. Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
  • Table 19.112. Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.113. Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.114. Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
  • Table 19.115. Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.116. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.117. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment, Base Scenario, 2019-2030 (USD Million)
  • Table 19.118. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.119. Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.120. Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.121. Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.122. Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.123. Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.124. Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.125. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.126. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography, Base Scenario, 2019-2030 (USD Million)
  • Table 19.127. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.128. Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.129. Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, Base Scenario, 2019-2030 (USD Million)
  • Table 19.130. Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.131. Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.132. Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, Base Scenario, 2019-2030 (USD Million)
  • Table 19.133. Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.134. Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.135. Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, Base Scenario, 2019-2030 (USD Million)
  • Table 19.136. Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.137. Patient Management Systems Market for Donor Eligibility Assessment, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.138. Patient Management Systems Market for Donor Eligibility Assessment, Base Scenario, 2019-2030 (USD Million)
  • Table 19.139. Patient Management Systems Market for Donor Eligibility Assessment, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.140. Patient Management Systems Market for Donor Eligibility Assessment: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.141. Patient Management Systems Market for Donor Eligibility Assessment: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.142. Patient Management Systems Market for Donor Eligibility Assessment: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.143. Patient Management Systems Market for Donor Eligibility Assessment: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.144. Patient Management Systems Market for Donor Eligibility Assessment: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.145. Patient Management Systems Market for Donor Eligibility Assessment: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.146. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.147. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment, Base Scenario, 2019-2030 (USD Million)
  • Table 19.148. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.149. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.150. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.151. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.152. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.153. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.154. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.155. Inventory Management Systems Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.156. Inventory Management Systems Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
  • Table 19.157. Inventory Management Systems Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.158. Inventory Management Systems Market for Sample Collection: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.159. Inventory Management Systems Market for Sample Collection: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.160. Inventory Management Systems Market for Sample Collection: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.161. Inventory Management Systems Market for Sample Collection: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.162. Inventory Management Systems Market for Sample Collection: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.163. Inventory Management Systems Market for Sample Collection: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.164. Laboratory Information Management Systems Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.165. Laboratory Information Management Systems Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
  • Table 19.166. Laboratory Information Management Systems Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.167. Laboratory Information Management Systems Market for Sample Collection: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.168. Laboratory Information Management Systems Market for Sample Collection: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.170. Laboratory Information Management Systems Market for Sample Collection: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.171. Laboratory Information Management Systems Market for Sample Collection: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.172. Laboratory Information Management Systems Market for Sample Collection: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.173. Laboratory Information Management Systems Market for Sample Collection: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.174. Logistics Management Systems Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.175. Logistics Management Systems Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
  • Table 19.176. Logistics Management Systems Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.177. Logistics Management Systems Market for Sample Collection: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.178. Logistics Management Systems Market for Sample Collection: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.179. Logistics Management Systems Market for Sample Collection: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.180. Logistics Management Systems Market for Sample Collection: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.181. Logistics Management Systems Market for Sample Collection: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.182. Logistics Management Systems Market for Sample Collection: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.183. Quality Management Systems Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.184. Quality Management Systems Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
  • Table 19.185. Quality Management Systems Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.186. Quality Management Systems Market for Sample Collection: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.187. Quality Management Systems Market for Sample Collection: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.188. Quality Management Systems Market for Sample Collection: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.189. Quality Management Systems Market for Sample Collection: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.190. Quality Management Systems Market for Sample Collection: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.191. Quality Management Systems Market for Sample Collection: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.192. Supply Chain Orchestration Platforms Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.193. Supply Chain Orchestration Platforms Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
  • Table 19.194. Supply Chain Orchestration Platforms Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.195. Supply Chain Orchestration Platforms Market for Sample Collection: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.196. Supply Chain Orchestration Platforms Market for Sample Collection: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.197. Supply Chain Orchestration Platforms Market for Sample Collection: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.198. Supply Chain Orchestration Platforms Market for Sample Collection: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.199. Supply Chain Orchestration Platforms Market for Sample Collection: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.200. Supply Chain Orchestration Platforms Market for Sample Collection: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.201. Enterprise Manufacturing Systems Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.202. Enterprise Manufacturing Systems Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
  • Table 19.203. Enterprise Manufacturing Systems Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19. 204. Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19. 205. Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19. 206. Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19. 207. Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19. 208. Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19. 209. Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.210. Inventory Management Systems Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.211. Inventory Management Systems Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
  • Table 19.212. Inventory Management Systems Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.213. Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.214. Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.215. Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.216. Inventory Management Systems Market for Manufacturing: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.217. Inventory Management Systems Market for Manufacturing: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.218. Inventory Management Systems Market for Manufacturing: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.219. Laboratory Information Management Systems Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.220. Laboratory Information Management Systems Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
  • Table 19.221. Laboratory Information Management Systems Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.222. Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.223. Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.224. Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.225. Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.226. Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.227. Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.228. Quality Management Systems Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.229. Quality Management Systems Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
  • Table 19.230. Quality Management Systems Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.231. Quality Management Systems Market for Manufacturing: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.232. Quality Management Systems Market for Manufacturing: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.233. Quality Management Systems Market for Manufacturing: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.234. Quality Management Systems Market for Manufacturing: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.235. Quality Management Systems Market for Manufacturing: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.236. Quality Management Systems Market for Manufacturing: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.237. Supply Chain Orchestration Platforms Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.238. Supply Chain Orchestration Platforms Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
  • Table 19.239. Supply Chain Orchestration Platforms Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.240. Supply Chain Orchestration Platforms Market for Manufacturing: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.241. Supply Chain Orchestration Platforms Market for Manufacturing: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.242. Supply Chain Orchestration Platforms Market for Manufacturing: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.243. Supply Chain Orchestration Platforms Market for Manufacturing: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.244. Supply Chain Orchestration Platforms Market for Manufacturing: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.245. Supply Chain Orchestration Platforms Market for Manufacturing: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.246. Logistics Management Systems Market for Logistics, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.247. Logistics Management Systems Market for Logistics, Base Scenario, 2019-2030 (USD Million)
  • Table 19.248. Logistics Management Systems Market for Logistics, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.249. Logistics Management Systems Market for Logistics: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.250. Logistics Management Systems Market for Logistics: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.251. Logistics Management Systems Market for Logistics: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.252. Logistics Management Systems Market for Logistics: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.253. Logistics Management Systems Market for Logistics: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.254. Logistics Management Systems Market for Logistics: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.255. Supply Chain Orchestration Platforms Market for Logistics, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.256. Supply Chain Orchestration Platforms Market for Logistics, Base Scenario, 2019-2030 (USD Million)
  • Table 19.257. Supply Chain Orchestration Platforms Market for Logistics, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.258. Supply Chain Orchestration Platforms Market for Logistics: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.259. Supply Chain Orchestration Platforms Market for Logistics: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.260. Supply Chain Orchestration Platforms Market for Logistics: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.261. Supply Chain Orchestration Platforms Market for Logistics: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.262. Supply Chain Orchestration Platforms Market for Logistics: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.263. Supply Chain Orchestration Platforms Market for Logistics: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.264. Patient Management Systems Market for Patient Verification and Treatment Follow-up, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.265. Patient Management Systems Market for Patient Verification and Treatment Follow-up, Base Scenario, 2019-2030 (USD Million)
  • Table 19.266. Patient Management Systems Market for Patient Verification and Treatment Follow-up, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.267. Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.268. Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.269. Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.270. Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.271. Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.272. Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.273. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.274. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up, Base Scenario, 2019-2030 (USD Million)
  • Table 19.275. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.276. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.277. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.278. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
  • Table 19.279. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
  • Table 19.280. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
  • Table 19.281. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)

List of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. 3P Biopharmaceuticals
  • 2. 4G Clinical
  • 3. ABB
  • 4. Abbott Informatics
  • 5. Accenture
  • 6. Adaptimmune Therapeutics
  • 7. Adents
  • 8. Adlib
  • 9. Advanced Therapy Treatment Centres
  • 10. Aegis
  • 11. AF Industry
  • 12. Agaram Technologies
  • 13. AgiLab
  • 14. AgileBio
  • 15. Aithent
  • 16. Alberta Cell Therapy Manufacturing
  • 17. AllCells
  • 18. AlloSource
  • 19. Alvotech
  • 20. Ambry Genetics
  • 21. Amgen
  • 22. Antares Vision
  • 23. Anterogen
  • 24. AntTail
  • 25. AODocs
  • 26. Aptean
  • 27. AQ Manager
  • 28. Aqxolt
  • 29. ArisGlobal
  • 30. ArunA Biomedical
  • 31. AssurX
  • 32. Asymptote
  • 33. Atara Biotherapeutics
  • 34. Atomos Hyla
  • 35. Aurea
  • 36. Autodesk
  • 37. Autolus Therapeutics
  • 38. Autoscribe Informatics
  • 39. AveXis
  • 40. Avita Medical
  • 41. Baptist Memorial Health Care
  • 42. BatchMaster Software
  • 43. BayaTree
  • 44. BC Platforms
  • 45. Benchling
  • 46. Benchmark
  • 47. Bika Lab Systems
  • 48. BioCision
  • 49. BioFortis
  • 50. Biokin Pharmaceutical
  • 51. BioLife Solutions
  • 52. BioSoft Integrators
  • 53. Biovault
  • 54. BIOVIA
  • 55. Birlasoft
  • 56. BizzMine
  • 57. Blaze Systems
  • 58. Blood Bank of Alaska
  • 59. Bluechiip
  • 60. bluecrux
  • 61. Boyum IT Solutions
  • 62. Bregal Sagemount
  • 63. Bristol-Myers Squibb
  • 64. Broekman Group
  • 65. Brooks Life Sciences
  • 66. Business Pointers
  • 67. Caladrius Biosciences
  • 68. Cambridge Biomedical
  • 69. Cambridge University Hospitals NHS Foundation Trust
  • 70. Camelot ITLab
  • 71. Camstar Systems
  • 72. Canaan Partners
  • 73. Canadian Tissue Repository Network
  • 74. CancerCare Manitoba
  • 75. Capgemini
  • 76. CareDx
  • 77. CareMetx
  • 78. Casdin Capital
  • 79. Cell and Gene Therapy Catapult
  • 80. Celularity
  • 81. Celyad
  • 82. Cenetron Diagnostics
  • 83. Cerner
  • 84. ChartFill
  • 85. Chiesi Farmaceutici
  • 86. Chiyoda System Technologies
  • 87. CIMx
  • 88. Clarkston Consulting
  • 89. Cleveland Institute for Computational Biology
  • 90. Clinical Ink
  • 91. CloudLIMS
  • 92. CobbleStone Software
  • 93. Codon Software
  • 94. Cognate BioServices
  • 95. Comaiba
  • 96. Conatus Pharmaceuticals
  • 97. Concerto Cloud Services
  • 98. Consummate Technologies
  • 99. Continental Technology Solutions
  • 100. COPAN Group
  • 101. CORDET
  • 102. Core Informatics
  • 103. COSMO CONSULT
  • 104. CoverMyMeds
  • 105. Credit Suisse
  • 106. CRISPR Therapeutics
  • 107. Cryo Store
  • 108. Cryogene Partners
  • 109. CRYO-LEA
  • 110. Cryoport
  • 111. CryoStem
  • 112. CryoTrack
  • 113. CSAM
  • 114. CSL Plasma
  • 115. Cubixx Solutions
  • 116. Cytolon
  • 117. Dacos
  • 118. Daedalus Software
  • 119. Daiichi Sankyo
  • 120. Data+ Research
  • 121. DataArt
  • 122. Database Integrations
  • 123. Databyran
  • 124. Datacor
  • 125. Dataworks Development
  • 126. Deacom
  • 127. Dell
  • 128. Deloitte
  • 129. Deltek
  • 130. Dendreon
  • 131. Deutsche Telekom
  • 132. DFJ
  • 133. DHL
  • 134. Digi-Trax
  • 135. DiscGenics
  • 136. Docbyte
  • 137. Docxellent
  • 138. Dooile
  • 139. Draper Associates
  • 140. eHealth Technologies
  • 141. EJADA
  • 142. Elinext
  • 143. Emad Trade House
  • 144. Emerson
  • 145. Endodiag
  • 146. Enhanced Information Solutions
  • 147. Enterprise System Partners
  • 148. Epeius Biotechnologies
  • 149. EuSoft
  • 150. EVERSANA™
  • 151. EXB Software
  • 152. Excellis Health Solutions
  • 153. EXTEDO
  • 154. Extract Systems
  • 155. e-Zest
  • 156. Factorytalk
  • 157. Factumsoft
  • 158. Faubel
  • 159. FedEx
  • 160. Ferdinand Cabanne Biobank Center
  • 161. FFF Enterprises
  • 162. Fibrocell Science
  • 163. Fidelity Biosciences
  • 164. FirstMark Capital
  • 165. Fishbowl
  • 166. Fisher Clinical Services
  • 167. Florida Hospital Cancer Center
  • 168. Foch Hospital
  • 169. F-Prime Capital Partners
  • 170. Fred Hutchinson Cancer Research Center
  • 171. French Epinal-Remiremont hospital group
  • 172. Gamida Cell
  • 173. GE Healthcare
  • 174. GE Ventures
  • 175. GEFCO
  • 176. Gen9
  • 177. Genea Biomedx
  • 178. Genedata
  • 179. Geneva Systems
  • 180. Genohm
  • 181. GenoLogics
  • 182. Georgian Partners
  • 183. Gilead Sciences
  • 184. GlaxoSmithKline
  • 185. Goldman Sachs
  • 186. GPI Group
  • 187. Gradalis
  • 188. Green Cross LabCell
  • 189. Grenoble Alpes University Hospital
  • 190. Gulf Software Distribution
  • 191. Gustave Roussy
  • 192. Haemonetics
  • 193. Haier Biomedical
  • 194. HeapTrace Technology
  • 195. Heat Biologics
  • 196. HemaCare
  • 197. Hemasoft Software
  • 198. HighPoint Solutions
  • 199. HighRes Biosolutions
  • 200. Hitachi
  • 201. Holostem Advanced Therapies
  • 202. HP Enterprise Group
  • 203. Human Stem Cells Institute
  • 204. Hypertrust Patient Data Care
  • 205. IBM
  • 206. ICON
  • 207. Ideagen
  • 208. IDESS
  • 209. IFS
  • 210. Immetacyte
  • 211. Immudex
  • 212. ImmunoCellular Therapeutics
  • 213. Indiana University Health
  • 214. Infinity Group
  • 215. Informeleon
  • 216. Informeleon LifeScience Technologies
  • 217. INFORS HT
  • 218. Innovate UK
  • 219. Innovation Connections
  • 220. Institute of Medical Biology
  • 221. Intelex
  • 222. Interactive Biosoftware
  • 223. Interactive Software
  • 224. International Air Transport Association
  • 225. International Genetically Engineered Machine Foundation
  • 226. International Stem Cell
  • 227. Iovance Biotherapeutics
  • 228. IPERION
  • 229. IQity
  • 230. IQMS
  • 231. IQVIA
  • 232. iSpecimen®
  • 233. I-Track Software
  • 234. JAF Consulting
  • 235. JAGGAER
  • 236. Japan Tissue Engineering
  • 237. JD Edwards
  • 238. Jeena
  • 239. Jeeves Information Systems
  • 240. Jinfonet Software
  • 241. KAIROS
  • 242. Kayentis
  • 243. KCAS Bioanalytical and Biomarker Services
  • 244. KCSA Strategic Communications
  • 245. Kiadis Pharma
  • 246. Kite Pharma
  • 247. KLATU Networks
  • 248. KLP Enterprises
  • 249. Kolon TissueGene
  • 250. Körber Medipak Systems
  • 251. Labcon
  • 252. Labii
  • 253. LabLogic Systems
  • 254. LabLynx
  • 255. LabVantage Solutions
  • 256. LabWare
  • 257. Larsen & Toubro Infotech
  • 258. Lead Edge Capital
  • 259. LifeConEx
  • 260. LifeForce Capital
  • 261. Limoges University Hospital
  • 262. Liventa Bioscience
  • 263. Llamawerx
  • 264. Logistyx Technologies
  • 265. Lonza
  • 266. Lynden International
  • 267. Magenta Therapeutics
  • 268. MAK-SYSTEM
  • 269. Management Science Associates
  • 270. MARKEN
  • 271. Marker Therapeutics
  • 272. MasterControl
  • 273. Mayo Clinic
  • 274. Mazik Global
  • 275. McKesson
  • 276. MD Logistics
  • 277. Medable
  • 278. MedCision
  • 279. Medical Research Network
  • 280. Medical University of Graz
  • 281. Medidata
  • 282. Medipost
  • 283. MediSapiens
  • 284. Mediware Information Systems
  • 285. MedNet Solutions
  • 286. Mendix
  • 287. Menlo Ventures
  • 288. Mesoblast
  • 289. Microsoft
  • 290. MicroStrategy
  • 291. Miller-Keystone Blood Center
  • 292. Miltenyi Biotec
  • 293. MiMedx Group
  • 294. Mindteck
  • 295. Modul-Bio
  • 296. Moffitt Cancer Center
  • 297. MolMed
  • 298. Montefiore Medical Center
  • 299. Montrium
  • 300. Morphotek
  • 301. Mount Sinai Medical
  • 302. Mustang Bio
  • 303. MyCellHub
  • 304. National Blood Transfusion Centre
  • 305. National Health Service Blood and Transplant
  • 306. Neotrident
  • 307. NetSuite
  • 308. Network Scientific
  • 309. New York Presbyterian Hospital
  • 310. New York University Abu Dhabi
  • 311. Nohla Therapeutics
  • 312. Northern Alliance Advanced Therapies Treatment Centre
  • 313. Noshaq
  • 314. Nous Infosystems
  • 315. Novartis
  • 316. Novatek International
  • 317. NTT Data
  • 318. NuVasive
  • 319. Nymi
  • 320. Oak HC/FT
  • 321. Oasis Infotech
  • 322. Ocimum Biosolutions
  • 323. Octal IT Solution
  • 324. Octapharma
  • 325. Octaware
  • 326. Odoo
  • 327. OmniComm
  • 328. Oncobiomed
  • 329. OpenSpecimen
  • 330. OpenXcell
  • 331. Opexa Therapeutics
  • 332. OptiProERP
  • 333. Oracle
  • 334. Orthofix
  • 335. OSIsoft
  • 336. Osys
  • 337. OTTR Complete Transplant Management
  • 338. Oxford BioMedica
  • 339. PAREXEL
  • 340. Parsec
  • 341. Pathomation
  • 342. PCX International
  • 343. Perseus PCI
  • 344. Persistent Systems
  • 345. Peter MacCallum Cancer Centre
  • 346. Petrichor Healthcare Capital Management
  • 347. Pharmicell
  • 348. Pilgrim Quality Solutions
  • 349. Planet Innovation
  • 350. PleaseTech
  • 351. Polar Speed
  • 352. Polarion
  • 353. POMS
  • 354. Poseida Therapeutics
  • 355. PricewaterhouseCoopers
  • 356. prime4services
  • 357. Priority Software
  • 358. Priveq Investment Fund IV
  • 359. Pro-curo Software
  • 360. ProfitKey
  • 361. Progeny Genetics
  • 362. Progeny Software
  • 363. ProMab Biotechnologies
  • 364. ProteoGenex
  • 365. Proteus Technologies
  • 366. Q2 Solutions
  • 367. QCMedchain
  • 368. QIAGEN
  • 369. Qualio
  • 370. Quality by Design
  • 371. Qualityze
  • 372. Qualsys
  • 373. Quick Life Science Group
  • 374. Rand Group
  • 375. RareChannels
  • 376. Redefine
  • 377. Reflow
  • 378. Reliance Life Sciences
  • 379. Replica Sistemi
  • 380. Rfgen Software
  • 381. ROC IT Solutions
  • 382. Roche
  • 383. Rockwell Automation
  • 384. Rootstock Software
  • 385. Roslin Cells
  • 386. RURO
  • 387. Sage
  • 388. salamanderU
  • 389. salesforce.com
  • 390. Samsung BioLogics
  • 391. Sanaria
  • 392. Sanpower Group
  • 393. SAP
  • 394. SapioSciences
  • 395. Sapphire
  • 396. Sarah Cannon Blood Cancer Network
  • 397. Sarla Technologies
  • 398. Savsu Technologies
  • 399. SciMed Technologies
  • 400. Scottish National Blood Transfusion Service
  • 401. Section 32
  • 402. sedApta Group
  • 403. SeerPharma
  • 404. SemanticBits
  • 405. Sensire
  • 406. Sentry BioPharma Services
  • 407. Shanghai Sunway Biotech
  • 408. Shanghai Wellthinic Technology
  • 409. ShipChain
  • 410. Sibiono GeneTech
  • 411. Siemens
  • 412. Sintec
  • 413. Software Point
  • 414. SOLABS
  • 415. SolutionsMax
  • 416. Spark Therapeutics
  • 417. Sparta
  • 418. SPC Consultants
  • 419. Specialised Therapeutics
  • 420. SPI Pharma
  • 421. STEINER
  • 422. Stem Cell Technology Centre
  • 423. Stemedica Cell Technologies
  • 424. STEMSOFT Software
  • 425. stemTrak
  • 426. Strategic Information Group
  • 427. SuprTecBox
  • 428. Suzuken
  • 429. Swinburne Universoty
  • 430. Synergy Resources
  • 431. SYSPRO
  • 432. Systec & Services
  • 433. SystImmune
  • 434. SZIENZ
  • 435. Tableau Software
  • 436. Takeda Pharmaceutical
  • 437. TECHNIDATA
  • 438. Telegraph Hill Partners
  • 439. Terumo
  • 440. Terumo BCT
  • 441. Tessa Therapeutics
  • 442. Thaddeus
  • 443. The CoFoundry
  • 444. The Faktory
  • 445. Thermo Fisher Scientific
  • 446. Thrive Capital
  • 447. TiGenix
  • 448. Tissue Solutions
  • 449. Titian Software
  • 450. Title21 Health Solutions
  • 451. Tmunity Therapeutics
  • 452. Total Specific Solutions
  • 453. Touchdown International
  • 454. Toyo Business Engineering
  • 455. TPG Capital
  • 456. TraceLink
  • 457. Triangle Research Labs
  • 458. Triumvirate Environmental
  • 459. TrueERP
  • 460. UMass Memorial Health Care System
  • 461. UNIGEN
  • 462. United Cargo®
  • 463. United Parcel Service
  • 464. Unity™ Lab Services
  • 465. University Cancer Institute
  • 466. University Hospitals of Strasbourg and Strasbourg University
  • 467. University of Bialystok
  • 468. University of Illinois
  • 469. University of Melbourne
  • 470. University of Minnesota's Molecular and Cellular Therapeutics Unit
  • 471. University of Sheffield
  • 472. ValueLabs
  • 473. Veeva Systems
  • 474. Velos
  • 475. Vericel
  • 476. Verse
  • 477. Versiti™
  • 478. Vestrics Solutions
  • 479. Vitro
  • 480. Vitrolife
  • 481. Vivaldi
  • 482. VMware
  • 483. Volition Capital
  • 484. Vulcan Capital
  • 485. WellSky™
  • 486. Werum IT Solutions
  • 487. WindMIL Therapeutics
  • 488. Woodfield Distribution
  • 489. WorkWise
  • 490. World Courier
  • 491. WuXi AppTec Advanced Therapies
  • 492. XynManagement
  • 493. Xyntek
  • 494. Y Combinator
  • 495. Yale-New Haven Hospital
  • 496. Yokogawa Solution Service
  • 497. ZenBio
  • 498. Zenith Technologies